Anxiety stack (non-pharmaceutical) — when SSRIs and benzodiazepines aren't the answer
For mild-to-moderate generalised anxiety, social-evaluative anxiety, or stress-driven somatic anxiety in adults who do not yet need (or do not tolerate, or have chosen not to take) SSRIs or benzodiazepines. The Foundation layer is daily, chronic, slow-onset — ashwagandha and Silexan-form lavender both have RCT evidence comparable in effect size to low-dose SSRIs at 6–10 weeks. The Performance layer is acute and situational — theanine and saffron act faster and dose-flexibly. The Optional layer addresses sleep-related anxiety and somatic tension.
For mild-to-moderate generalised anxiety, social-evaluative anxiety, or stress-driven somatic anxiety in adults who do not yet need (or do not tolerate, or have chosen not to take) SSRIs or benzodiazepines. The Foundation layer is daily, chronic, slow-onset — ashwagandha and Silexan-form lavender both have RCT evidence comparable in effect size to low-dose SSRIs at 6–10 weeks.
Important framing: this stack is an adjunct, not a substitute. If you have severe anxiety, panic disorder with frequent attacks, PTSD with intrusive symptoms, or significant functional impairment, see a clinician — CBT, exposure therapy, and (when indicated) an SSRI have meaningfully larger effect sizes than any supplement here. Use this stack for situations where pharmaceutical treatment is not appropriate, not available, or being deferred while psychotherapy takes hold.
TL;DR — the stack
| Supplement | Layer | Dose & timing | Score |
|---|---|---|---|
| Ashwagandha (KSM-66) | Foundation | 300–600 mg/day, with breakfast or split AM/PM | 78 |
| Lavender oil (Silexan) | Foundation | 80 mg/day standardised softgel, with food | 80 |
| Magnesium glycinate | Foundation | 200–400 mg elemental, evening | 82 |
| L-theanine | Performance | 200–400 mg, 30–60 min before stressor (acute) or twice daily (chronic) | 68 |
| Saffron (standardised extract) | Performance | 28–30 mg/day standardised (Affron 28 mg or equivalent) | 66 |
| Passionflower (Passiflora incarnata) | Optional | 500 mg extract or 1–2 g dried herb, evening | 55 |
| Lemon balm (Melissa officinalis) | Optional | 300–600 mg/day standardised extract, split | 54 |
Per-supplement detail
Dose & timing. 300–600 mg/day of a standardised root extract (KSM-66 5% withanolides at 300 mg, or Shoden at 120 mg). Take with breakfast, or split between AM and PM. Effect builds over 4–8 weeks.
Why. Ashwagandha appears to act via HPA-axis modulation with downstream effects on cortisol and subjective anxiety. Pratte et al. 2014 (PMID 25405876) reviewed 5 RCTs in anxiety-spectrum populations and found ashwagandha consistently reduced anxiety scores (Hamilton, PSS, Beck) with moderate effect sizes vs placebo. Lopresti et al. 2019 (PMID 31517876) randomised 60 chronically stressed adults to ashwagandha 240 mg or placebo for 60 days and reported significant reductions in Hamilton anxiety scores and morning cortisol.
Funder mix. Mix of academic and supplement-industry funded (KSM-66 trials by Ixoreal, Shoden trials by Arjuna). Effect direction replicates across funder categories.
Notes. Avoid in pregnancy (uterine-stimulant evidence in animals), with thyroid hormone (may raise T4/T3), and in autoimmune thyroid disease (Hashimoto's flare reports). Hepatotoxicity is rare but documented — stop and see a clinician if you develop jaundice, dark urine, or RUQ pain.
Dose & timing. 80 mg/day of Silexan-standardised oral lavender oil softgel (a specific standardised preparation; generic lavender oil capsules have not been studied to the same standard). Take with food. Onset is 1–2 weeks for partial effect, 4–6 weeks for full effect.
Why. Silexan is the most rigorously studied oral lavender preparation, with effects on subjective anxiety comparable to low-dose paroxetine and lorazepam in head-to-head trials. Möller et al. 2019 (PMID 30837799) pooled five double-blind RCTs of Silexan 80 mg in generalised anxiety disorder (n=1,173) and found significant reductions in Hamilton anxiety scores vs placebo, with effect size comparable to SSRIs. Kasper et al. 2014 (PMID 24411671) compared Silexan to paroxetine 20 mg in GAD and reported non-inferiority on the primary anxiety outcome with better tolerability.
Funder mix. Trials largely funded by Schwabe (Silexan manufacturer). Trial quality is high, but independent replications are limited — keep the score off Tier 1.
Notes. Eructation (lavender-flavoured burps) is the most common side effect. Insufficient pregnancy and breastfeeding data — avoid. No serotonin-syndrome cases reported when combined with SSRIs, but the trial data on combination use is thin.
Dose & timing. 200–400 mg elemental magnesium glycinate with the evening meal or 30–60 min before bed. Glycinate form is best for anxiety/sleep dosing — citrate works but is laxative at this dose.
Why. Magnesium modulates NMDA receptor activity, supports GABA-A receptor function, and is involved in HPA-axis regulation. Boyle et al. 2017 (PMID 28445426) reviewed 18 trials of magnesium for anxiety subtypes and concluded the strongest evidence is for mild-to-moderate anxiety in adults with low-normal magnesium status — typical of low-vegetable diets and high-alcohol intake. Effect sizes are smaller than for ashwagandha or Silexan but additive.
Funder mix. Mostly academic.
Notes. Separate ≥4 h from levothyroxine and from tetracycline or fluoroquinolone antibiotics. Reduce dose with eGFR <30. Glycinate (also called bisglycinate) is a chelate; "magnesium oxide" at the same elemental dose is absorbed much less.
Dose & timing. 200–400 mg taken 30–60 minutes before an anticipated stressor (presentation, exam, difficult meeting) for acute use, or 200 mg twice daily for chronic support. No tolerance documented at these doses.
Why. L-theanine increases alpha-wave activity in the EEG and modulates glutamate-GABA balance, producing a "calm-alert" state without sedation. Williams et al. 2020 (PMID 32319495) systematically reviewed 9 RCTs and found theanine reduced acute-stress responses (heart rate, salivary IgA, subjective stress) at 200–400 mg single doses, with smaller chronic-anxiety effects at 200–400 mg/day over 4–8 weeks.
Funder mix. Mix of academic and Suntheanine/Taiyo industry-funded trials. Effect replicates across funder categories.
Notes. Combines cleanly with caffeine (the cognitive-stack form). Safe across pregnancy at modest doses but data is limited — defer to clinician guidance. No serotonergic action; no documented SSRI interaction.
Dose & timing. 28–30 mg/day of a standardised saffron extract (Affron 28 mg or equivalent; the dose used in most trials is 30 mg/day split AM/PM). Onset is 2–4 weeks for partial effect.
Why. Saffron's active constituents (crocins, safranal) appear to modulate serotonergic and GABAergic signalling. Hausenblas et al. 2013 (PMID 24299602) meta-analysed 5 RCTs and found saffron 30 mg/day produced reductions in depression and anxiety symptoms comparable to fluoxetine 20 mg over 6–8 weeks. Lopresti et al. 2018 (PMID 30056830) extended the evidence base into adolescent and young-adult anxiety populations with similar effect sizes.
Funder mix. Mix of academic and Pharmactive/Affron-funded trials. Independent replications exist.
Notes. Avoid in pregnancy (uterine-stimulating at high doses). Theoretical serotonergic action — combine with SSRIs/SNRIs only under prescriber supervision (no serotonin-syndrome cases reported at supplemental doses, but watch for signs).
Dose & timing. 500 mg of a standardised extract, or 1–2 g of dried herb in tea/tincture, in the evening. Use as a sleep-onset adjunct in anxious-arousal insomnia.
Why. Passionflower contains flavonoids (chrysin, vitexin) with GABA-A receptor positive modulator activity. Akhondzadeh et al. 2001 (PMID 11679026) randomised 36 adults with GAD to passionflower vs oxazepam and found comparable anxiety reduction with less daytime sedation. Trauer et al. 2017 review (covered in subsequent integrative-medicine reviews) noted passionflower's smaller but consistent effect in milder anxiety.
Funder mix. Largely academic in the original Akhondzadeh trial; later trials are mixed.
Notes. Mild sedation expected — don't drive after evening dose if you're not used to it. Avoid in pregnancy (uterine-stimulating). Combines well with magnesium glycinate; avoid stacking with benzodiazepines, GABA-ergic alcohol use, or first-generation antihistamines.
Dose & timing. 300–600 mg/day of a standardised extract, split AM and PM. Cymbopol/Bluenesse-standardised forms have the cleanest data.
Why. Lemon balm's rosmarinic-acid constituents inhibit GABA-transaminase, raising synaptic GABA. Cases et al. 2011 (PMID 22042502) randomised 20 anxious adults to standardised lemon balm and found reductions in anxiety symptoms and stress over 15 days. Effect sizes are modest but reproducible.
Funder mix. Mix of academic and Vital Solutions (Bluenesse-form) funding.
Notes. Generally well-tolerated. Mild sedation possible. Avoid in pregnancy (insufficient data). Theoretically reduces thyroid hormone secretion at very high doses — relevant for Graves' but not at standard supplemental doses.
Daily timing — when to take what
MiddayL-theanine 200 mg (if dosing chronically). Lemon balm PM dose.
Pre-stressorL-theanine 200–400 mg, 30–60 min before known stressor (acute use only — presentation, exam, social event).
EveningMagnesium glycinate 200–400 mg with dinner. Saffron PM dose (15 mg). Ashwagandha 300 mg (if split).
Pre-bedPassionflower 500 mg (if anxious-arousal insomnia is a problem). See the sleep-onset stack for fuller coverage.
Within-stack synergies
The Foundation trio of ashwagandha + Silexan + magnesium glycinate hits three independent mechanisms — HPA-axis modulation, oral lavender oil's distinct anxiolytic action (not fully mapped but functionally GABA-A-adjacent in animal models), and NMDA/GABA-A modulation. The combination has not been studied head-to-head against any individual component, but the mechanisms are non-overlapping enough that additive effect is reasonable.
L-theanine + saffron work cleanly together — different putative mechanisms (theanine modulates fast glutamate/GABA balance; saffron acts via serotonergic and slower modulation). No documented antagonism.
Magnesium glycinate + passionflower pair well for the bedtime slot if anxiety-driven sleep onset is a major component. Both have mild sedative effect; together they reach a useful evening anxiolysis without daytime carryover.
Caution: Avoid stacking passionflower + lemon balm + magnesium glycinate all at the same bedtime dose — additive sedation can produce next-day grogginess. Pick one or two for the evening slot, not three.
Interactions to watch
- SSRIs, SNRIs, MAOIs, triptans, tramadol. Saffron has serotonergic action; ashwagandha and Silexan have less clear serotonergic activity. Combining any of these with the prescription serotonergic agents above carries a theoretical serotonin-syndrome risk. No supplement-related cases at standard doses, but discuss with the prescriber before adding.
- Benzodiazepines, gabapentinoids, sedating antihistamines, alcohol. Passionflower, lemon balm, and magnesium are all mildly sedating. Combining them with benzodiazepines, pregabalin/gabapentin, diphenhydramine, doxylamine, or alcohol risks excessive sedation and impaired driving. Avoid evening alcohol with this stack.
- Thyroid medication. Ashwagandha may raise T4/T3 and TSH-suppressed levels — check thyroid function 8–12 weeks after starting if you take levothyroxine or have autoimmune thyroid disease. Magnesium chelates levothyroxine — separate by ≥4 h.
- Antihypertensives. Ashwagandha may lower blood pressure modestly; check home BP if you're on multiple antihypertensives or are prone to orthostatic symptoms.
- Diabetes medication. Ashwagandha may lower fasting glucose; monitor if you're on sulfonylureas or insulin.
- Lithium. Lemon balm and passionflower have CNS-depressant activity; magnesium may shift lithium clearance. Avoid all three without psychiatrist supervision.
- Hepatotoxicity flag for ashwagandha. Rare but documented case reports of acute hepatitis (Suryawanshi et al. 2023, PMID 36529390). Stop and seek care if jaundice, dark urine, or RUQ pain develop.
- Pregnancy / breastfeeding. Drop ashwagandha, Silexan, saffron, passionflower, lemon balm — all have uterine-stimulating signals or insufficient lactation safety data. Magnesium glycinate and modest-dose L-theanine are acceptable with clinician sign-off.
Don't bother — what to skip
These are commonly marketed for anxiety relief but the evidence does not support routine use — or carries a risk profile that outweighs the modest benefit.
- Oral GABA supplements. GABA does not meaningfully cross the blood-brain barrier at oral doses. Boonstra et al. 2015 (PMID 26579216) reviewed the human evidence and concluded the central nervous system effects of oral GABA cannot be explained by direct CNS action; reported subjective effects are likely peripheral (enteric nervous system) and/or placebo. PharmaGABA and related "natural" forms share the same BBB issue — small or absent CNS effect.
- Kava (high-dose extract). Kava has a real acute anxiolytic effect — Pittler and Ernst 2003 (PMID 12535473) Cochrane review confirmed it. But hepatotoxicity case reports led to regulatory withdrawals in Germany, Switzerland, France, and the UK (Teschke et al. 2008, PMID 18638680). FDA and EMA continue to warn. The risk-benefit is not favourable when ashwagandha and Silexan offer comparable anxiolysis without the liver signal.
- CBD for generalised anxiety. CBD's anxiolytic literature is dominated by single-dose social-anxiety challenge studies. Chronic-anxiety RCTs are sparse and inconsistent, doses studied (300–600 mg/day) are far above what most OTC products deliver, and Larsen and Shahinas 2020 (PMID 32509258) noted heterogeneity that precluded meta-analytic conclusions for chronic GAD. Spend the money elsewhere until the chronic-use evidence catches up.
- 5-HTP and L-tryptophan as anxiolytics. Acutely raise serotonin but evidence for chronic anxiety reduction is poor. Bigger problem: combination with SSRIs, SNRIs, MAOIs, triptans, or linezolid risks serotonin syndrome — documented in case reports. Marketing as a "natural serotonin booster" obscures this risk. Saffron has cleaner evidence and a smaller drug-interaction surface.
Sources
- Pratte MA, Nanavati KB, Young V, Morley CP. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera). J Altern Complement Med. 2014;20(12):901–908. PMID: 25405876.
- Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: a randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019;98(37):e17186. PMID: 31517876.
- Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S. Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci. 2019;269(2):183–193. PMID: 30837799.
- Kasper S, Gastpar M, Müller WE, et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder — a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol. 2014;17(6):859–869. PMID: 24411671.
- Boyle NB, Lawton C, Dye L. The effects of magnesium supplementation on subjective anxiety and stress — a systematic review. Nutrients. 2017;9(5):429. PMID: 28445426.
- Williams JL, Everett JM, D'Cunha NM, et al. The effects of green tea amino acid L-theanine consumption on the ability to manage stress and anxiety levels: a systematic review. Plant Foods Hum Nutr. 2020;75(1):12–23. PMID: 32319495.
- Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med. 2013;11(6):377–383. PMID: 24299602.
- Lopresti AL, Drummond PD, Inarejos-García AM, Prodanov M. Affron, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: a randomised, double-blind, placebo-controlled study. J Affect Disord. 2018;232:349–357. PMID: 30056830.
- Akhondzadeh S, Naghavi HR, Vazirian M, et al. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001;26(5):363–367. PMID: 11679026.
- Cases J, Ibarra A, Feuillère N, et al. Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Med J Nutrition Metab. 2011;4(3):211–218. PMID: 22042502.
- Suryawanshi MV, Gujarathi PP, Mulla T, Bagban I. Ashwagandha-induced liver injury: report of a case and updated review. J Family Med Prim Care. 2023;12(9):2167–2170. PMID: 36529390.
- Boonstra E, de Kleijn R, Colzato LS, et al. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Front Psychol. 2015;6:1520. PMID: 26579216.
- Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003;(1):CD003383. PMID: 12535473.
- Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol. 2008;20(12):1182–1193. PMID: 18638680.
- Larsen C, Shahinas J. Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials. J Clin Med Res. 2020;12(3):129–141. PMID: 32509258.